Background: The current review aims to present the beneficial effects of SGLT2 inhibitors (dapagliflozin and empagliflozin) on several hemodynamic parameters such as blood pressure, filtration pressure at the level of the glomerular capillaries, and the improvement of the preload and afterload of heart muscle. In order to stop chronic kidney disease (CKD) from progressing, SGLT2 inhibitors have become an important disease-modifying treatment. Materials and methods: Recent clinical studies have shown the success of these drugs in treating heart failure, reducing the risk of cardiovascular events, hospitalization, and mortality. Results: The hemodynamic effects of SGLT2 inhibitors include a diuretic effect, due to reduced sodium reabsorption. Also, at this level, numerous studies have confirmed the beneficial effect of dapagliflozin in patients with chronic kidney disease, associated with a 44% reduced risk of progression in this pathology. SGLT2 inhibitors are associated with a reduction in blood pressure and weight loss, because of their diuretic effect, especially empagliflozin, which can explain the beneficial effects in patients with heart failure. In addition, mainly empagliflozin reduces stiffness and arterial resistance. Conclusions: Although the exact mechanism of action is unknown, SGLT2 inhibitors reduce the interstitial volume by blocking the tubular reabsorption of glucose. This leads to reduced blood pressure and enhanced endothelial function. Consequently, there have been improvements in hospitalization and fatality rates. Because of their beneficial effects, these medications have been guidelines for managing heart failure and chronic kidney disease.

Current evidence suggests that dyslipidemia in patients with diabetes mellitus is associated with multiple microvascular and macrovascular complications. The prolonged failure to achieve glycemic and lipid profile targets increases cardiovascular risk, mortality, and the costs associated with medical care. This study aimed to explore the correlations between dyslipidemia and glycemic control in patients with diabetes, evaluate variations in lipid profiles, examine the impact of dyslipidemia on diabetes-related complications and assess the effectiveness of lipid-lowering treatments. A cohort observational study was conducted on 304 patients hospitalized at the Emergency County Hospital in Oradea, Bihor, located in Northwest Romania, over a two-year period from 2022 to 2023. The study included data on diabetes control (fasting blood glucose, HbA1c), associated conditions including diabetes complications, laboratory analyses-lipid profile, creatinine, urea, albuminuria-anthropometric data, and home medication. In the group without dyslipidemia, the mean HbA1c value was 8.96±2.81, compared to 9.70±2.80 in the dyslipidemia group. The mean blood glucose level was 207.44±126.09 in the group without dyslipidemia and 257.77±140.68 in the dyslipidemia group (p=0.048). Coronary artery disease was significantly more common in patients with dyslipidemia (58.9%) than in those without (4.6%) (p=0.004). Uric acid levels were higher in patients with dyslipidemia (p=0.048). Lipid-lowering therapy reduced high lipid values, but a significant percentage of patients on treatment still exhibited elevated cholesterol, LDL, and triglyceride levels. In patients with poorly controlled diabetes, dyslipidemia associates with poorer glycemic control, greater obesity levels, cardiovascular diseases, particularly coronary artery disease and peripheral arterial disease, as well as chronic kidney disease. Despite treatment, the lipid profile continues to remain elevated.

Sepsis-induced myocardial dysfunction (SIMD) is one of the major predictors of morbidity and mortality of sepsis. A high percentage of patients with SIMD develop a status similar to cardiogenic shock. A high level of bacterial lipopolysaccharide (LPS) associated with an overexpression of CD14 acts as the trigger for the release of a broad spectrum of cytokines. Our study aimed to understand the correlation between septic cardiomyopathy and CD14 immunohistochemical expression. The study included 29 patients who died of septic shock. Increased values of membranous CD14 and soluble CD14 in the heart tissue were correlated with adverse patient evolution. A high cellular expression of CD14 was noted in the study group vs. the control group (p = 0.0013). Therefore, a close positive association between the amount of LPS related to sCD14 and the cellular expression of mCD14 is probable. By extrapolation, we suggest that a large amount of sCD14 detected in the cardiac tissue will activate the mCD14–TRL4–LBP–LPS complex, which in turn will induce an inadequate immune response, resulting in heart damage proportional to the amount of LPS. CD14 could represent a valuable marker for septic cardiomyopathy; thus, apoptosis of cardiomyocytes could be foreseen by its high value.

Background/Objectives: Small-cell lung cancer (SCLC) is a highly aggressive malignancy with an emerging molecular classification based on the expression of the transcription factors ASCL1, NEUROD1, and POU2F3. This study aimed to explore the relationship between these novel subtypes and the tumor immune microenvironment (TIME), particularly CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs). Methods: In 51 cases of patients with SCLC, immunohistochemical (IHC) stains for ASCL1, NEUROD1, POU2F3, CD56, Ki67, CD8, and CD4 were performed. H-scores for the novel transcription factors were calculated to determine tumor subtype. CD8+ and CD4+ TIL counts were averaged across 10 high-power fields. The Kruskal–Wallis test and subsequent post hoc Dunn tests were used to determine the differences in transcription factor expression and TILs across subtypes. Results: In our cohort, 68.62% of our cases were SCLC-A, 9.80% were SCLC-N, 7.84% were SCLC-P, and 13.72% were SCLC-I. Significant differences were observed in the expression of ASCL1, NEUROD1, and POU2F3 across subtypes. CD8+ TILs were more abundant in SCLC-P and SCLC-I. CD8+ TILs were negatively correlated with ASCL1 expression (p < 0.05) and positively correlated with POU2F3 expression (p < 0.005). Conclusions: This study highlights the need to integrate the novel SCLC classification with data regarding the TIME to better inform patient prognosis and treatment.

Oxidative stress is manifested at the maternal-fetal interface from the beginning of pregnancy. It plays a role both in the normal development of the placenta and in the pathophysiology of complications: miscarriage, preeclampsia, intrauterine growth restriction (IUGR) and premature rupture of membranes. We studied from an immunohistochemical point of view nine placentas from pregnant women between the ages of 35 and 40 who had miscarriages in the absence of an obvious medical cause with a control group consisting of 9 normal, up to term placentas. We studied the anti-Gluthatione antibody and METH1 patterns of staining. The results showed an obvious association of low values of GLUTH and METH1 with miscarriages.

Molecular pathology-driven oncologic diagnostics—genomic profiling, transcriptomics, proteomics, and, increasingly, artificial intelligence applied to tissue and liquid biopsy—can only be as accurate as the biospecimens on which they are performed. Biobanks are the infrastructures that secure this foundation, linking donors, biological samples, and data to discovery and, through the pathology interface, back to diagnosis. Their scientific and diagnostic value, however, is determined less by the number of specimens stored than by the rigor of the guidelines under which those specimens are collected, processed, annotated, governed, and shared. The normative landscape has changed considerably in the last three years: the ISBER Best Practices reached their fifth edition (2023), the NCI Best Practices were comprehensively revised (2026), the Standard PREanalytical Code (SPREC) was updated to version 4.0 (2024/2025), MIABIS Core reached version 3.0 (2024), the 2024 revision of the Declaration of Helsinki explicitly anchored biobank governance to the Declaration of Taipei, the European Health Data Space Regulation (EU) 2025/327 entered into force, and ISO 20387—the accreditation standard for biobanks—is undergoing its first full revision. This review synthesizes the current (2026) status of international biobanking standards, ethical and legal frameworks, pre-analytical and quality management requirements, data and interoperability standards, and sustainability models, drawing on more than 200 sources with emphasis on the 2023–2026 literature. Standards are presented not as an inventory but as an operational system, organized along the biobanking workflow from donor consent to sample distribution and impact tracking. On this basis, we propose a phased, guideline-anchored roadmap and a start-up checklist to help new teams establish a real-world biobank—particularly hospital-integrated biobanks in settings without a mature national biobanking infrastructure—and we review comprehensively the financial, operational, regulatory, and societal challenges that determine whether a new biobank thrives or stalls. Particular attention is given to the specimen classes and quality controls on which molecular tumor diagnostics depend—FFPE tissue and its sequencing artifacts, fresh-frozen tissue, liquid biopsy analytes, and DV200-gated derivative quality—and to the interface between research biobanking and the accredited diagnostic laboratory, which is set out explicitly because the two are governed by different standards. We further provide explicit, endpoint-specific operational control of warm and cold ischemia, a quality-control framework for advanced patient-derived models (xenografts and organoids) and their interface with dedicated model cores, an explicit statement of the evidence underlying the practical recommendations, and a dedicated limitations section. The review is intended as a reference piece for biobankers, pathologists, clinician-researchers, quality managers, and institutional decision-makers building the biobanks on which the coming decade of precision oncology will depend.